Soluble Interleukin-2 Receptor: A Potential Marker for Monitoring Disease Activity in IgG4-Related Disease
Table 3
Treatment response in IgG4-RD.
P
IgG4 before treatment
IgG4 after treatment
sIL-2R before treatment
sIL-2R after treatment
CRP before treatment
CRP after treatment
IgG4-RD RI before treatment
IgG4-RD RI after treatment
1
17.7
10.10
3695
3443
1.8
1.6
9
3
2
3.18
3.32
3441
2864
1.0
2.5
4
2
4
5.44
0.46
3700
1600
0.5
0.9
6
1
6
13.48
6.70
5800
2900
0.3
0.3
10
4
7
13.40
3.27
5151
3653
4.7
1.4
10
3
8
1.65
0.28
5700
2800
1.0
0.6
6
1
9
10.30
4.99
3900
1800
50.0
4.5
7
3
10
25.25
4.58
5900
4300
80.0
35.0
6
2
11
5.40
2.79
3500
819
4.8
0.4
5
1
12
1.65
1.54
8135
3700
10.0
7.5
6
1
14
1.57
1.33
3100
2160
5.2
10.0
6
3
17
5.55
1.84
5300
2200
0.3
0.3
6
1
20
8.82
1.28
6135
2222
2.8
38
4
0
24
3.44
1.35
7100
3616
31
6.8
6
1
26
1.29
1.76
10,800
5000
8.0
7.6
4
3
Treatment response in IgG4-RD with levels of serum IgG4, CRP, and sIL-2R before and after treatment. The disease activity has been measured using the IgG4-RD RI. Normal range of serum IgG4 is 0.08–1.40 g/l, normal range of serum sIL-2R is below 2500 pg/ml, and normal range of CRP is below 10 mg/l. CRP = C-reactive protein; IgG4-RD RI = IgG4-Related Disease Responder Index.
